Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Fengzhi Li

Showing results (1-10 of 122) with videos related to

Pageof 13
Sort By:
American Journal of Cancer Research|June 25, 2014
Anticancer drug FL118 is more than a survivin inhibitor: where is the Achilles' heel of cancer?Fengzhi Li
Journal of Cellular Physiology|August 28, 2003
Survivin study: what is the next wave?Fengzhi Li
Molecules and Cells|April 25, 2009
Every single cell clones from cancer cell lines growing tumors in vivo may not invalidate the cancer stem cell conceptFengzhi Li
International Review of Cell and Molecular Biology|July 30, 2013
Discovery of survivin inhibitors and beyond: FL118 as a proof of conceptFengzhi Li
Biotechniques|March 25, 2004
Silencing of antiapoptotic survivin gene by multiple approaches of RNA interference technologyXiang Ling, Fengzhi Li
Journal of Experimental & Clinical Cancer Research : CR|December 31, 2015
New trends for overcoming ABCG2/BCRP-mediated resistance to cancer therapiesDavid Westover, Fengzhi Li
Journal of Cellular Physiology|March 25, 2006
Survivin study: an update of "what is the next wave"?Fengzhi Li, Xiang Ling
American Journal of Cancer Research|December 18, 2018
Multiple mechanisms involved in a low concentration of FL118 enhancement of AMR-MeOAc to induce pancreatic cancer cell apoptosis and growth inhibitionThangaiyan Rabi, Fengzhi Li
American Journal of Translational Research|April 11, 2013
An intravenous (i.v.) route-compatible formulation of FL118, a survivin, Mcl-1, XIAP, and cIAP2 selective inhibitor, improves FL118 antitumor efficacy and therapeutic index (TI)Xiang Ling, Fengzhi Li
The American Journal of Pathology|July 4, 2006
Role of the Survivin gene in pathophysiologyFengzhi Li, Michael G Brattain
Pageof 13

Showing results (1-10 of 122) with videos related to

Sort By:
Pageof 13
American Journal of Cancer Research|June 25, 2014
Anticancer drug FL118 is more than a survivin inhibitor: where is the Achilles' heel of cancer?Fengzhi Li
Journal of Cellular Physiology|August 28, 2003
Survivin study: what is the next wave?Fengzhi Li
Molecules and Cells|April 25, 2009
Every single cell clones from cancer cell lines growing tumors in vivo may not invalidate the cancer stem cell conceptFengzhi Li
International Review of Cell and Molecular Biology|July 30, 2013
Discovery of survivin inhibitors and beyond: FL118 as a proof of conceptFengzhi Li
Biotechniques|March 25, 2004
Silencing of antiapoptotic survivin gene by multiple approaches of RNA interference technologyXiang Ling, Fengzhi Li
Journal of Experimental & Clinical Cancer Research : CR|December 31, 2015
New trends for overcoming ABCG2/BCRP-mediated resistance to cancer therapiesDavid Westover, Fengzhi Li
Journal of Cellular Physiology|March 25, 2006
Survivin study: an update of "what is the next wave"?Fengzhi Li, Xiang Ling
American Journal of Cancer Research|December 18, 2018
Multiple mechanisms involved in a low concentration of FL118 enhancement of AMR-MeOAc to induce pancreatic cancer cell apoptosis and growth inhibitionThangaiyan Rabi, Fengzhi Li
American Journal of Translational Research|April 11, 2013
An intravenous (i.v.) route-compatible formulation of FL118, a survivin, Mcl-1, XIAP, and cIAP2 selective inhibitor, improves FL118 antitumor efficacy and therapeutic index (TI)Xiang Ling, Fengzhi Li
The American Journal of Pathology|July 4, 2006
Role of the Survivin gene in pathophysiologyFengzhi Li, Michael G Brattain
Pageof 13